FDA Expands Vyvgart Approval to All Adults With gMG
The label expansion will include adults with AChR-Ab-negative gMG, making efgartigimod the first and only approved treatment for all serotypes of the rare neuromuscular disease. Medscape Medical News
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.